Kaleido Biosciences, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2020. For the quarter, the company reported loss from operations of $19,300,000 against $18,973,000 a year ago. Net loss was $20,013,000 against $19,510,000 a year ago. Net loss per share basic and diluted was $0.56 against $0.65 a year ago. For the full year, the company reported loss from operations of $79,874,000 against $86,660,000 a year ago. Net loss was $81,620,000 against $86,331,000 a year ago. Net loss per share basic and diluted was $2.44 against $3.36 a year ago.